Korea Pfizer (CEO O Dong-wook) announced that, following a Ministry of Health and Welfare notice, its TNF inhibitor Enbrel (etanercept) will be covered by the national health insurance for patients with severe active non‑radiographic axial spondyloarthritis (nr‑axSpA) starting September 1.
Non‑radiographic axial spondyloarthritis is a type of axial spondyloarthritis where X‑ray imaging does not show clear structural damage of the sacroiliac joints, but patients still experience significant pain and disease burden.
Actualizaciones regulatorias15 sept 2026•3 min de lectura
Korea Pfizer’s Enbrel Gains Health Insurance Coverage for nr-axSpA
Korea Pfizer announced that etanercept (Enbrel) will be reimbursed by national health insurance for severe active non‑radiographic axial spondyloarthritis patients starting September 1, expanding treatment access.
Recopilado por el equipo de Pharmacountry · Fuente: KPA News
Temas:
Calificaciones
(0)
(0)
(0)
(0)
(0)
Deja tu valoración